Search

Your search keyword '"Anne-Sophie Lamort"' showing total 2 results
Start Over Author "Anne-Sophie Lamort" Publisher wiley
2 results on '"Anne-Sophie Lamort"'

1. Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors

Author

Laura V. Klotz, Yves Courty, Michael Lindner, Agnès Petit‐Courty, Anja Stowasser, Ina Koch, Martin E. Eichhorn, Ioannis Lilis, Alicia Morresi‐Hauf, Kristina A. M. Arendt, Mario Pepe, Ioanna Giopanou, Giannoula Ntaliarda, Sabine J. Behrend, Maria Oplopoiou, Valérie Gissot, Serge Guyetant, Sylvain Marchand‐Adam, Jürgen Behr, Jan‐Christian Kaiser, Rudolf A. Hatz, Anne‐Sophie Lamort, and Georgios T. Stathopoulos

Subjects
LADC, lung adenocarcinoma, obstruction, smoking, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract A comprehensive characterization of lung adenocarcinoma (LADC) clinical features is currently missing. We prospectively evaluated Caucasian patients with early‐stage LADC. Patients with LADC diagnosed between 2011 and 2015 were prospectively assessed for lung resection with curative intent. Fifty clinical, pathologic, radiologic, and molecular variables were recorded. Patients were followed till death/study conclusion. The main findings were compared to a separate cohort from France. Of 1943 patients evaluated, 366 were enrolled (18.8%; 181 female; 75 never‐smokers; 28% of registered Bavarian cases over the study period). Smoking and obstruction were significantly more prevalent in GLAD compared with adult Bavarians (P 7.5 and 3.6 years, respectively. Patients aged 65 years, resected >60 days postdiagnosis, with abnormal FVC/DLCOVA, N2/N3 stage, or solid histology had significantly decreased survival estimates. These were fit into a weighted locoregional LADC death risk score that outperformed pTNM7 in predicting survival in the GLAD and in our second cohort. We define the clinical gestalt of locoregional LADC and provide a new clinical tool to predict survival, findings that may aid future management and research design.

Published
2019
Full Text
View/download PDF

2. KRAS signaling in malignant pleural mesothelioma

Author

Antonia Marazioti, Anthi C Krontira, Sabine J Behrend, Georgia A Giotopoulou, Giannoula Ntaliarda, Christophe Blanquart, Hasan Bayram, Marianthi Iliopoulou, Malamati Vreka, Lilith Trassl, Mario A A Pepe, Caroline M Hackl, Laura V Klotz, Stefanie A I Weiss, Ina Koch, Michael Lindner, Rudolph A Hatz, Juergen Behr, Darcy E Wagner, Helen Papadaki, Sophia G Antimisiaris, Didier Jean, Sophie Deshayes, Marc Grégoire, Özgecan Kayalar, Deniz Mortazavi, Şükrü Dilege, Serhan Tanju, Suat Erus, Ömer Yavuz, Pınar Bulutay, Pınar Fırat, Ioannis Psallidas, Magda Spella, Ioanna Giopanou, Ioannis Lilis, Anne‐Sophie Lamort, Georgios T Stathopoulos, Ludwig Maximilian University [Munich] (LMU), University of Patras [Patras], German Center for Lung Research, Immunogenic Cell Death and Mesothelioma Therapy (CRCINA-ÉQUIPE 4), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Koç University, Asklepios Klinikum Uckermark GmbH, Lund University [Lund], Institute of Chemical Engineering and High Temperature Chemical Processes, (FORTH/ICE-HT), Foundation for Research and Technology - Hellas (FORTH), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), University of Patras, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Bernardo, Elizabeth, Bayram, Hasan (ORCID 0000-0002-5236-766X & YÖK ID 4890), Dilege, Mustafa Şükrü (ORCID 0000-0002-1071-5291 & YÖK ID 122573), Tanju, Serhan (ORCID 0000-0002-2363-233X & YÖK ID 214690), Erus, Suat (ORCID 0000-0002-6162-3266 & YÖK ID 175565), Yavuz, Ömer, Bulutay, Pınar (ORCID 0000-0001-5497-1513 & YÖK ID 133565), Fırat, Pınar Arıkan (ORCID 0000-0001-8340-2678 & YÖK ID 207545), Marazioti, Antonia, Krontira, Anthi C., Behrend, Sabine J., Giotopoulou, Georgia A., Ntaliarda, Giannoula, Blanquart, Christophe, Iliopoulou, Marianthi, Vreka, Malamati, Trassl, Lilith, Pepe, Mario A. A., Hackl, Caroline M., Klotz, Laura, V, Weiss, Stefanie A., I, Koch, Ina, Lindner, Michael, Hatz, Rudolph A., Behr, Juergen, Wagner, Darcy E., Papadaki, Helen, Antimisiaris, Sophia G., Jean, Didier, Deshayes, Sophie, Gregoire, Marc, Kayalar, Özgecan, Mortazavi, Deniz, Psallidas, Ioannis, Spella, Magda, Giopanou, Ioanna, Lilis, Ioannis, Lamort, Anne-Sophie, Stathopoulos, Georgios T., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine

Subjects
Mesothelioma, Medicine (General), Lung Neoplasms, endocrine system diseases, Pleural Neoplasms, Respiratory System, [SDV.CAN]Life Sciences [q-bio]/Cancer, QH426-470, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Mice, 0302 clinical medicine, R5-920, [SDV.CAN] Life Sciences [q-bio]/Cancer, Genetics, KRAS, Animals, Humans, BAP1, TP53, neoplasms, 030304 developmental biology, 0303 health sciences, Tumor Suppressor Proteins, Mesothelioma, Malignant, Bap1, Kras, Nf2, Tp53, Asbestos, asbestos, Research and experimental medicine, TP53 Subject Categories Cancer, respiratory tract diseases, NF2, 030220 oncology & carcinogenesis, Molecular Medicine, Ubiquitin Thiolesterase, Signal Transduction
Abstract

Malignant pleural mesothelioma (MPM) arises from mesothelial cells lining the pleural cavity of asbestos-exposed individuals and rapidly leads to death. MPM harbors loss-of-function mutations in BAP1, NF2, CDKN2A, and TP53, but isolated deletion of these genes alone in mice does not cause MPM and mouse models of the disease are sparse. Here, we show that a proportion of human MPM harbor point mutations, copy number alterations, and overexpression of KRAS with or without TP53 changes. These are likely pathogenic, since ectopic expression of mutant KRAS(G12D) in the pleural mesothelium of conditional mice causes epithelioid MPM and cooperates with TP53 deletion to drive a more aggressive disease form with biphasic features and pleural effusions. Murine MPM cell lines derived from these tumors carry the initiating KRAS(G12D) lesions, secondary Bap1 alterations, and human MPM-like gene expression profiles. Moreover, they are transplantable and actionable by KRAS inhibition. Our results indicate that KRAS alterations alone or in accomplice with TP53 alterations likely play an important and underestimated role in a proportion of patients with MPM, which warrants further exploration., European Union (EU); Horizon 2020; European Research Council 2010 Starting Independent Investigator; ERC Proof of Concept 2015 (ERC-PoC-2015); German Research Society; ALTERNATIVE; German Ministry for Education and Research; German Center for Lung Research Translational Research Grant; Greek State Scholarship Foundation Program; European Union (EU); European Union Social Fund; Greek National Fund; Reinforcement of Postdoctoral Researchers-1 stand 2nd cycles; General Secretariat for Research and Innovation; Hellenic Foundation for Research and Innovation; REPSIRE European Respiratory Society Fellowship; Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Institut de Recherche en Sante Respiratoire des Pays de la Loire; National Research Agency Programme d' Investissements d' Avenir; Pays de la Loire Region Research Program; Ligue Contrele Cancer; Chancellerie des Universites de Paris; Projekt DEAL

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results